Four-fold or greater amplification (4.46–11.10-fold) of HER2 was observed in 7 samples (tumor sample 26, 49, 53, 56, 58, 61, and 62), whereas 17 samples (tumor sample 2, 10, 15, 18, 27, 28, 31, 41, 45, 48, 51, 52, 54, 55, 59, 64, and 65) had a more moderate HER2 amplification (2.23–3.75-fold). Here, ERBB2 is linked to neoplasm.